Prognostic value of tissue plasminogen activator (tPA) in patients with epithelial ovarian cancer undergoing chemotherapy

Abstract

Objectives: Tissue plasminogen activator (tPA) is a key enzyme for fibrin degradation and the proteolytic defense against formation of the thrombotic endothelial deposits. tPA is involved in carcinogenesis but its exact role in tumor biology is not very well understood and a prognostic value of tPA remains ambiguous in different cancers. The aim of the study was to assess the prognostic value of plasma tPA in patients with epithelial ovarian cancer (EOC) in the course of the first line chemotherapy. Material and methods: the study covered 60 patients with EOC who underwent the 1 st line chemotherapy. Plasma tPA was assessed at onset, after 3 and 6 cycles of chemotherapy. The groups were stratified according to tPA level at onset of chemotherapy (low tPA group < 6.5 mg/L, N = 37 and high tPA group > 6.5 mg/L, N = 23). Survival analysis was repeated for the cutoff of tPA level at 6.5 mg/L and 5.1 mg/L after 3 and 6 cycles. Results: Only subjects with tPA > 6.5 mg/L at onset of chemotherapy had a significantly lower probability of a 5-year survival (34.8% vs. 72.7%, P < 0.006) and lower chance for disease free survival within 5 years (39.3% vs. 72.7%, P < 0.014). tPA < 6.5 mg/L plasma level evaluated at onset of chemotherapy was an independent marker of better overall survival (RR = 0.44, 95%CI = 0.19-0.98) but not disease-free survival. Conclusions: Plasma tPA may serve as a marker of survival if assessed at onset of the first line chemotherapy in patients with ovarian cancer.

Hypercoagulability State Combined with Post-Treatment Hypofibrinolysis in Invasive Breast Cancer: A Seven-Year Follow-Up Evaluating Disease-Free and Overall Survival

“…There is not much data supporting a potential predictive value of t-PA with respect to the adjuvant chemotherapy received. Teliga-Czajkowska et al presented that a high t-PA plasma level at the onset of chemotherapy was associated with shorter OS and DFS in patients with ovarian cancer, but they found no significant differences in DFS and OS after three and six cycles of chemotherapy [ 30 ]. Another study conducted by Corte et al showed no significant relation between intra-tumoural t-PA levels and RFS and OS prognosis in breast cancer patients in accordance with the type of systemic adjuvant therapy received.…”

Exploration of differential methylation-driven genes to identify key epigenetic genes for prognosis of ovarian serous cystadenocarcinoma

“…In ovarian cancer, PLAT may be closely related to the prognosis of ovarian cancer. High plasma concentration of tissue plasminogen activator (tPA) before surgery is determined as an independent biomarker for shorter OS in patients with ovarian cancer and the expression of PLAT in plasma before the start of rst-line chemotherapy could be used as an indicator to predict survival of patients with ovarian cancer (29). TMOD1 has been proved previously that TMOD1 elevation could enhance the malignant phenotype of TNBC via inducing expression of MMP13 (30).…”

Deep learning on image-omics data in identifying prognostic immune biomarkers for ovarian cancer

“…These genes are likely expressed by CD73_1 and CD73_2, two different CAF subtypes. Among these genes, CCDC85B, DDAH1, EFEMP2, F2RL1, ITGB1, LOX, LDLR, MFGE8, MICAL2, MKL1, MSRB3, NCAM1, NPTX, PLAT, SLC2A3, SPSB1, and VASN have been described as promotors of tumor cell growth, invasion, and migration, as well as angiogenesis [26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41] (Table S4, Fig. S7).…”